If you've ever waited anxiously for your Medicare Advantage plan to approve a prescription — calling your doctor's office, calling the insurer, calling again — you already understand why this proposed rule matters. The Centers for Medicare & Medicaid Services has put forward a proposal that would require Medicare Advantage plans to meet specific deadlines when deciding whether to approve or deny prior authorization requests for prescription drugs. Right now, there is no uniform federal clock ticking on those decisions for drug coverage within Medicare Advantage plans, and the result is that some beneficiaries wait days or even weeks to find out whether their plan will cover a medication their doctor has already prescribed.
Prior authorization — often called prior auth or PA — is the process by which your Medicare Advantage insurer requires your doctor to get advance approval before the plan will cover certain drugs or services. It exists, in theory, to ensure that expensive or potentially risky treatments are medically appropriate. In practice, it has become one of the most complained-about features of Medicare Advantage coverage. A 2022 report from the HHS Office of Inspector General found that Medicare Advantage plans denied prior authorization requests that met Medicare coverage rules at a significant rate, and that many of those denials were later overturned on appeal. The problem isn't just the denials themselves — it's the time it takes to get any answer at all, during which patients may go without medication or pay out of pocket.
The CMS proposal would establish distinct timelines for standard versus urgent prior authorization requests for Part D drugs covered under Medicare Advantage plans. Urgent requests — situations where waiting the standard timeframe could seriously jeopardize a patient's health — would need to be decided more quickly than routine requests. While the exact hour and day counts in the final rule may be refined before publication, the framework mirrors the approach CMS already uses for medical service prior authorizations under Medicare Advantage, where plans must respond to standard requests within 14 calendar days and urgent requests within 72 hours. Applying similar logic to drug coverage would represent a significant tightening of current practice.
For beneficiaries, the practical impact would be most visible in situations involving specialty drugs, brand-name medications with no generic equivalent, or drugs that require step therapy — meaning your plan requires you to try a cheaper drug first before approving the one your doctor originally prescribed. These are the categories where prior auth delays tend to be longest and most consequential. Someone managing a chronic condition like rheumatoid arthritis, multiple sclerosis, or certain cancers may be prescribed a biologic or specialty drug that costs thousands of dollars per month without insurance. A two-week prior auth delay in that context isn't an inconvenience — it can mean a gap in treatment that affects health outcomes.
The proposal also has implications for how quickly beneficiaries can access the appeals process. Under current Medicare rules, if your Medicare Advantage plan denies a prior authorization request, you have the right to appeal — first through the plan's internal process, then through an independent review entity, and ultimately through administrative law judges and federal courts if needed. But if a plan takes 10 days just to issue a denial, that eats into the time you have to act, and it delays the point at which you can even begin the appeals clock. Faster mandatory decision deadlines mean faster denials when denials happen, which paradoxically gives beneficiaries more time and runway to fight back through the appeals system.
It's worth understanding how this proposal fits into a broader regulatory push. In 2023, CMS finalized a rule requiring Medicare Advantage plans to make prior authorization decisions for medical services within specific timeframes and to ensure that their prior auth criteria are based on current evidence and Medicare coverage rules — not more restrictive internal standards. That rule, which took effect for the 2024 plan year, was a significant step. The new drug-focused proposal extends that same accountability logic to the prescription drug side of Medicare Advantage. Together, these rules signal that CMS is treating prior authorization abuse as a systemic problem requiring structural fixes, not just guidance.
If you are enrolled in a Medicare Advantage plan in 2026 and you've experienced prior authorization delays for prescription drugs, there are steps you can take right now regardless of where this proposal lands. First, ask your doctor's office to flag your request as urgent if your medical situation warrants it — plans are already required to treat urgent requests differently, and your physician's documentation of medical necessity carries weight. Second, if your plan denies a prior auth request, request a written explanation of the denial and ask your doctor to submit a peer-to-peer review request, where your physician speaks directly with the plan's medical reviewer. This step alone reverses a meaningful share of initial denials. Third, if you're denied and believe the denial is wrong, file a formal appeal immediately — don't wait. You can start the appeals process by calling 1-800-MEDICARE or by contacting your plan directly in writing.
For beneficiaries who are shopping for Medicare Advantage coverage during the Annual Enrollment Period, which runs October 15 through December 7 each year, prior authorization policies are a legitimate factor to compare across plans. Medicare's Plan Finder tool at medicare.gov allows you to look up specific drugs under each plan's formulary, but it does not always make prior authorization requirements immediately obvious. You can call each plan directly and ask: does this drug require prior authorization, and what is your typical turnaround time for standard and urgent requests? Plans are required to answer these questions.
State insurance commissioners do not regulate Medicare Advantage prior authorization timelines — that authority sits with CMS at the federal level — but your State Health Insurance Assistance Program, known as SHIP, can help you navigate a prior auth dispute at no cost. SHIP counselors are trained volunteers and staff who provide free, unbiased help to Medicare beneficiaries. You can find your local SHIP contact through the Medicare.gov website or by calling 1-800-MEDICARE.
The proposed rule is subject to a public comment period before it can be finalized, which means it may be modified based on feedback from insurers, patient advocates, physicians, and beneficiaries themselves. CMS has historically accepted public comments through regulations.gov, and individual beneficiaries are permitted and encouraged to submit comments describing their personal experiences with prior authorization delays. Those comments become part of the official record and can influence the final rule's language and timelines. If you or a family member has experienced a harmful delay in getting a drug approved through Medicare Advantage, your account — submitted in plain language — carries real weight in that process.